Half of 22 heavily pretreated R/R AML patients achieved a composite complete remission when they received SENTI-202 doses manufactured from cells bearing a specific donor attribute — a 50% response rate in a population where approved therapies routinely fail more than 80% of patients. That single biomarker finding, which Senti Bio calls the “Donor X attribute,” is now the structural backbone of the company’s entire manufacturing and regulatory strategy, and the FDA’s receptivity to a single-arm pivotal design suggests the agency agrees the signal is real enough to pursue registration without a randomized comparator arm.
The Donor X discovery reframes what was previously a heterogeneous Phase 1 dataset into something far more actionable. The attribute appears in roughly 50% of adult donors, operates independently of HLA or KIR matching, and is detectable prospectively — meaning Senti Bio can screen and lock donor selection before manufacturing rather than retrospectively explaining variance. For an allogeneic off-the-shelf CAR-NK program, that is not a minor operational detail. It eliminates the largest source of batch-to-batch efficacy noise and gives the pivotal trial a defined, enrichable patient population. The FDA’s endorsement of a single-arm, multi-center design following the Type B RMAT meeting confirms the agency views MRD-negative complete remission rates — already described as comparing favorably to approved therapies across the full 22-patient cohort — as a credible registrational endpoint in this indication.
The financial picture is precarious but deliberately managed. Cash stood at $8.9 million at quarter-end against a $7.5 million quarterly burn rate, leaving less than five weeks of runway on the balance sheet alone. The $10 million initial tranche from Celadon Partners closes in May and extends that runway, while the additional $30 million tranche remains subject to investor election — not a guarantee. The $6.9 million lease modification gain flattered the Q1 net loss figure of $4.2 million; strip that out and operating losses remain substantial relative to a company now carrying essentially no cash cushion. R&D spend dropped to $5.3 million from $9.3 million year-over-year, which reflects genuine cost discipline but also signals a lean operating model that leaves almost no margin for manufacturing delays as the pivotal trial design is finalized.
The single metric that will determine whether this program reaches registration is the MRD-negative composite CR rate in Donor X-selected patients across the pivotal cohort — if that 50% signal holds in a prospectively enrolled, multi-center setting, the single-arm design becomes a viable NDA package; if it regresses toward the full-cohort average, no amount of regulatory goodwill survives the data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
